BAY 3605349
Alternative Names: BAY-3605349; VVD Keap1 Act - Bayer; VVD NRF2 inhibitor - Bayer; VVD-130037Latest Information Update: 04 Jul 2025
At a glance
- Originator Vividion Therapeutics
- Developer Bayer
- Class Antineoplastics; Small molecules
- Mechanism of Action KEAP1 protein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 25 Apr 2025 Pharmacodynamics and pharmacokinetics data from preclinical studies in Solid tumours were presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025) .
- 20 Jan 2023 Bayer plans to file an IND application for Cancer (Bayer pipeline, January 2023)
- 20 Jan 2023 Preclinical trials in Solid tumours in Germany (unspecified route) before January 2023 (Bayer pipeline, January 2023)